RecruitingNCT06781034

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies


Sponsor

Centre Hospitalier Universitaire de Nīmes

Enrollment

128 participants

Start Date

Feb 3, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying None, pure observational study for people with acute lobar haematoma and cerebral hemorrhage. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNone, pure observational study

None, pure observational study


Locations(1)

CHU de Nîmes

Nîmes, Gard, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06781034


Related Trials